NEPH (Nephros) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


NEPH Nephros Inc NEPH
63 GF Score
Price $3.35
GF Value $2.87
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nephros's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

NEPH vs MLSS, HBIO, FEMY: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Instruments & Supplies subindustry, Nephros's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nephros Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Nephros's Margin of Safety % (DCF FCF Based) falls into.


NEPH
63GF Score
Nephros Inc NEPH
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.35 is trading 16.7% above its estimated GF Value™ of $2.87. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $2.87 vs. price of $3.35 (16.7% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score

Get the complete analysis for NEPH

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price
$2.87
GF Value